[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperuricemia-with-or-without-gout\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperuricemia-with-or-without-gout":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641938","tart-cherry-citrate-effervescent-tablet-for-urate-lowering-therapy-in-participants-with-asymptomatic-hyperuricemia-100641938",false,"NCT07613138","Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia","Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia: A Study Protocol for a Single-Center, Randomized, Placebo-Controlled Trial","TaCCi-HUA","Inclusion Criteria:\n\n1. Aged 18 to 65 years, regardless of sex;\n2. Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol\u002FL and 540 μmol\u002FL (for those without comorbidities) or between 420 μmol\u002FL and 480 μmol\u002FL (for those with at least one of the following comorbidities: hypertension, dyslipidemia, diabetes mellitus, obesity, stroke, coronary heart disease, heart failure, or CKD stage ≥2);\n3. Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares;\n4. Voluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Known allergy to any of the study medications, food products, or their components; current allergies; or known hypersensitivity;\n2. Active liver disease or cirrhosis, or liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\>2 times the upper limit of normal (ULN);\n3. Acute infection or active gastrointestinal ulcers;\n4. History of thyroid dysfunction;\n5. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin;\n6. Severe cardiac diseases, such as decompensated heart failure (NYHA class III or IV), unstable angina, or a history of myocardial infarction within the previous 12 months;\n7. Renal cysts, medullary sponge kidney, or other obstructive nephropathies;\n8. Rheumatoid arthritis requiring treatment or arthropathies due to other causes;\n9. Current use of medications that affect urate levels, including febuxostat, allopurinol, benzbromarone, probenecid, azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, pyrazinamide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (\\>325 mg\u002Fday) or other salicylates, losartan, or intravenous colchicine;\n10. Secondary hyperuricemia due to hematologic disorders, renal diseases, or radiotherapy\u002Fchemotherapy for malignancies;\n11. Brain disorders with impaired judgment, or mental disorders that preclude cooperation;\n12. Alcohol or substance abuse;\n13. Participation in another clinical trial within the three months prior to screening;\n14. Malignancy or active tuberculosis;\n15. Presence of other concurrent conditions that, in the investigator's judgment, may affect the efficacy evaluation or result in poor compliance;\n16. Use of glucocorticoids;\n17. Any other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment in this trial.","ALL","18 Years","65 Years",{"count":21,"type":22},196,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms).\n\nThe main question it aims to answer is:\n\nDoes taking tart cherry citrate effervescent tablets lower uric acid levels more effectively than taking a placebo (inactive) tablet, when both groups also receive lifestyle guidance?\n\nResearchers will compare two groups of participants. Both groups will receive lifestyle guidance (advice on diet and exercise). In addition:\n\n* One group will take the tart cherry citrate effervescent tablets.\n* The other group will take a placebo effervescent tablet (looks and tastes the same but contains no active ingredient).\n\nThe study will last 24 weeks.\n\nParticipants will:\n\n* Take the assigned effervescent tablet twice daily for 24 weeks\n* Follow lifestyle guidance for diet and exercise\n* Attend scheduled clinic visits for checkups and tests\n* Provide blood and urine samples for testing",[28],"Hyperuricemia With or Without Gout",[30,31,32,33],"hyperuricemia","uric acid","tart cherry","citrate","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2026-06-04",{"date":42,"type":22},"2028-05-01",{"name":44,"class":45},"Beijing Zhecheng Biotechnology Co., Ltd.","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100619546","phase-1-safety-and-food-effect-on-single-dose-bioavailability-of-f-02-2-na-in-healthy-adult-subjects-100619546","NCT07346027","Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects","A Randomized, Open Labeled, Two-period, Two-sequence Crossover, Phase 1 Study of F-02-2-Na Tablets in Healthy Adult Subjects：Assessment of Food Effect on Single-Dose Bioavailability","Inclusion Criteria:\n\n* 1\\. The subjects should fully understand the purpose, nature, process of the study and the possible adverse reactions, voluntarily act as subjects, and sign the informed consent form before the start of any research procedures.\n* 2\\. Healthy male or female subjects aged 18 to 45 years old (inclusive).\n* 3\\. The body weight for male and female subjects should be ≥ 50.0 kg and ≥ 45.0 kg, respectively; the body mass index (BMI) should be between 19 kg\u002Fm² and 26 kg\u002Fm² (inclusive).\n* 4\\. The subjects should have normal results or abnormal results without clinical significance in vital signs check, physical examination, clinical laboratory tests (Complete Blood Count (CBC), urine analysis, blood biochemistry, coagulation panel, free thyroid function tests), chest X-ray, liver and renal color ultrasound and 12-lead electrocardiogram.\n* 5\\. Normal renal function as determined by Investigator following review of clinical laboratory test results, including eGFR ≥ 90 mL\u002Fmin\u002F1.73 m².\n* 6\\. The subjects (including male subjects) should have no plans for having children from screening until 6 months after the last dose and should voluntarily take effective contraceptive measures and have no plans for sperm or egg donation.\n* 7\\. The subjects should be able to communicate well with the researchers and understand and comply with the requirements of this study.\n\nExclusion Criteria:\n\n* 1\\. Subjects with a specific allergic history (such as asthma, urticaria, eczema, etc.) or those with an allergic constitution (such as those known to be allergic to two or more substances), or those with a known history of allergy to F-02-2-Na and related excipients (ascertained through inquiry).\n* 2\\. Subjects who have had an acute illness within two weeks before the first drug administration (ascertained through inquiry).\n* 3\\. Subjects with diseases of important organs or systems (including but not limited to liver, kidney, nervous system, blood, endocrine system, lungs, immune system, mental health, cardiovascular and cerebrovascular system, gastrointestinal tract, skin, metabolism, bone and joints, etc.) that are considered clinically significant by the researcher, or those with a history of such serious diseases; or those with a history of tumor (ascertained through inquiry).\n* 4\\. Subjects with a history of gastrointestinal, liver, kidney, and thyroid diseases that can affect drug absorption or metabolism (ascertained through inquiry).\n* 5\\. Subjects with a history of gout (ascertained through inquiry).\n* 6\\. Subjects who have used any medications (including any prescription drugs, over-the-counter drugs, traditional Chinese herbal medicines) and health products within two weeks before the first drug administration (ascertained through inquiry).\n* 7\\. Subjects who have used any mercaptopurine hydrate or thiopurine drugs within four weeks before the study (ascertained through inquiry).\n* 8\\. Subjects who have heavily consumed, within 2 weeks prior to the first dose, or ingested within 48 hours prior to dosing, beverages containing caffeine or alcohol, or foods known to affect drug metabolism (such as chocolate, pitaya, mango, pomelo, carambola, guava, orange, grapefruit, or grapefruit products). (ascertained through inquiry)\n* 9\\. Subjects who have undergone major surgical procedures (excluding diagnostic surgical procedures) within six months before the study , or those who plan to have surgery during the research period, or those who have undergone surgeries that, in the judgment of the researcher, can affect drug absorption, distribution, metabolism, and excretion (ascertained through inquiry).\n* 10\\. Subjects who have received vaccination within three months before the study (ascertained through inquiry).\n* 11\\. Subjects who have participated in any other clinical trial within 3 months prior to the current study. (Note: The end date is defined as the date of completion\u002Fexit from the previous clinical trial.) (ascertained through inquiry).\n* 12\\. Subjects who have donated blood within three months before the study, or those whose total blood loss due to blood donation or other reasons has reached or exceeded 400 mL within six months (ascertained through inquiry).\n* 13\\. Subjects who, on average, consumed more than 14 units of alcohol per week over the past year, or those unable to abstain from alcohol during the study period, or individuals with a breath alcohol test result greater than 0.0 mg\u002F100 mL (ascertained through inquiry\u002Fexamination).\n* 14\\. Subjects who smoke more than 5 cigarettes per day on average within three months before the study, or those who cannot stop using any tobacco products during the study (ascertained through inquiry).\n* 15\\. Subjects with a history of drug abuse (including the repeated and excessive use of various narcotic drugs and psychotropic substances for non-medical purposes) or positive results in drug abuse screening (including morphine, methamphetamine, ketamine, MDMA (3,4-methylenedioxymethamphetamine), cannabis (tetrahydrocannabinolic acid), etc.) within the past year (ascertained through inquiry and examination).\n* 16\\. Subjects with a positive result in any item of the infectious disease examination during the screening period (including hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus antibody, and treponema pallidum antibody) (examination).\n* 17\\. Subjects who cannot tolerate venipuncture\u002Findwelling needle or those with a history of fainting at the sight of needles or blood (ascertained through inquiry).\n* 18\\. Subjects with difficult venous blood collection (ascertained through inquiry).\n* 19\\. Subjects with lactose intolerance (ascertained through inquiry). 20. Subjects with special dietary requirements and who cannot accept the unified diet (ascertained through inquiry).\n* 21\\. Subjects with dysphagia (ascertained through inquiry).\n* 22\\. Other subjects are deemed unsuitable for participation by the researcher.\n* 23\\. In addition to the above requirements, female subjects who meet the following conditions should also be excluded:\n* a. Those who have used oral contraceptives within 30 days before the study (ascertained through inquiry).\n* b. Those who have used long-acting estrogen or progesterone injections (including progesterone-containing intrauterine contraceptive devices) or implanted tablets within 6 months before the study (ascertained through inquiry).\n* c. Those who have unprotected sexual intercourse with their partners within 14 days before the study (ascertained through inquiry).\n* d. Those with a positive blood pregnancy test result (examination).\n* e. Pregnant or lactating women (ascertained through inquiry).",true,"45 Years",{"count":57,"type":22},12,[59],"PHASE1","The study is to evaluate the impact of food on the pharmacokinetics of F-02-2-Na in healthy adult subjects by observing the changes in the drug's pharmacokinetic profile-particularly in its absorption process-before and after food intake.",[28],"NOT_YET_RECRUITING","2026-06-15",{"date":37,"type":38},{"date":66,"type":22},"2026-07-01",{"date":68,"type":22},"2026-09-01",{"name":70,"class":71},"Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100603851","the-effects-of-a-probiotic-food-supplement-in-hyperuricaemia-100603851","NCT07141888","The Effects of a Probiotic Food Supplement in Hyperuricaemia","The Effects of a Novel Probiotic Food Supplement in Hyperuricaemia - Towards Development of an Individualised Treatment Strategy","Bugs4U-PoC","Inclusion Criteria:\n\n1. Signed informed consent prior to any study-related procedures\n2. Age 18-80 years old\n3. BMI range 17.5-40 kg\u002Fm2\n4. Blood uric acid above 405 μmol\u002Fl (6.8 mg\u002Fdl)\n5. Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages) during the study\n6. Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study\n\nExclusion Criteria:\n\n1. Recent (within last month) episode of gout\n2. Diagnosis of type 1 diabetes\n3. Diagnosed inflammatory bowel disease (IBD)\n4. Current diagnosis of psychiatric disease\u002Fs or syndromes\n5. Current diagnosis of neurodegenerative disease\n6. Current pregnancy or breastfeeding\n7. History of complicated gastrointestinal surgery\n8. (Partial) resection of the small intestine or colon\n9. Regular use of urate-lowering treatment (apart from allopurinol) in the month prior to inclusion\n10. Oral or intravenous administration of antibiotics and\u002For corticosteroids in the 4 months prior to inclusion\n11. Regular use of any non-steroidal anti-inflammatory drug (NSAID) during the last month prior to inclusion (apart from low-dose acetylsalicylic acid)\n12. Consumption of more than 9 standard glasses of alcohol-containing drinks per week and\u002For more than 4 standard glasses per occasion\n13. Regular use of probiotic or prebiotic supplementation in the month prior to inclusion\n14. Any condition or intake of medication which could substantially interfere with the outcome of the study, as decided by the principal investigator's discretion","80 Years",{"count":82,"type":22},99,[25],"The overall aim of the project is to determine whether a daily intake of health-promoting bacteria, known as probiotics, with or without a dietary fiber, affects uric acid levels in individuals with elevated levels of uric acid in the blood (hyperuricemia). Additionally, the project will investigate which individuals benefit from this dietary supplement and which do not, based on factors such as gut microbiota composition and function, dietary habits, genetic factors, and inflammatory status. The ultimate goal is to develop a personalized therapy for hyperuricemia.\n\nAt the beginning of the study, blood samples will be taken to determine uric acid levels and 99 individuals with hyperuricemia will be invited to participate in a 6-week intervention study with daily intake of dietary supplements. To examine the effect of the supplement on various health variables, blood, urine, stool, and breath samples will be collected on several occasions.\n\nTo better understand the underlying factors of hyperuricemia, questionnaire data and results from biological will be compared between participants with normal versus elevated uric acid levels. Furthermore, different outcome parameters from questionnaires and samples before and after supplement intake will be compared. In addition, various methods for estimating dietary intake will be investigated and compared with each other.",[28],"2026-03-26",{"date":88,"type":38},"2026-03-27",{"date":90,"type":38},"2025-12-16",{"date":92,"type":22},"2027-12",{"name":94,"class":45},"Örebro University, Sweden"]